Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,404,812
  • Shares Outstanding, K 160,756
  • Annual Sales, $ 441,760 K
  • Annual Income, $ -281,580 K
  • 60-Month Beta 0.62
  • Price/Sales 7.12
  • Price/Cash Flow N/A
  • Price/Book 6.09
Trade ACAD with:

Options Overview Details

View History
  • Implied Volatility 81.29% ( +7.40%)
  • Historical Volatility 49.80%
  • IV Percentile 59%
  • IV Rank 41.94%
  • IV High 140.61% on 03/09/21
  • IV Low 38.43% on 06/03/21
  • Put/Call Vol Ratio 0.28
  • Today's Volume 2,255
  • Volume Avg (30-Day) 851
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 21,354
  • Open Int (30-Day) 33,420

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.25
  • Number of Estimates 10
  • High Estimate -0.14
  • Low Estimate -0.37
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +40.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.89 +1.39%
on 01/18/22
25.09 -15.58%
on 12/28/21
-0.27 (-1.26%)
since 12/21/21
3-Month
16.88 +25.47%
on 10/27/21
27.19 -22.10%
on 12/20/21
+3.13 (+17.34%)
since 10/21/21
52-Week
15.68 +35.08%
on 09/14/21
54.58 -61.19%
on 01/25/21
-30.83 (-59.28%)
since 01/21/21

Most Recent Stories

More News
Phillips (PHG) Blends 3D Mapping With Zenition, Aids Prospects

Phillips (PHG) integrates AI and 3D mapping capabilities it its Mobile C-Arm System, Zenition, enhancing its diagnostic imaging portfolio.

PHG : 33.12 (-1.98%)
ALKS : 24.00 (-1.32%)
ACAD : 21.18 (-1.44%)
AHCO : 18.40 (-5.15%)
Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise....

ACAD : 21.18 (-1.44%)
AXSM : 23.70 (-11.25%)
ANAB : 30.99 (-0.39%)
STOK : 18.10 (-0.22%)
Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies

Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.

ACAD : 21.18 (-1.44%)
ANAB : 30.99 (-0.39%)
DTIL : 4.59 (-7.65%)
STOK : 18.10 (-0.22%)
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Stoke Therapeutics, Inc. (Nasdaq: STOK) announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based...

ACAD : 21.18 (-1.44%)
STOK : 18.10 (-0.22%)
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 10:30 a.m. Eastern Time, followed...

ACAD : 21.18 (-1.44%)
ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA

ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.

SRPT : 63.47 (-1.73%)
ACAD : 21.18 (-1.44%)
VTVT : 0.7689 (-10.58%)
DTIL : 4.59 (-7.65%)
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it plans to resubmit its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated...

ACAD : 21.18 (-1.44%)
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective immediately. Mr. Schneyer has served as the...

ACAD : 21.18 (-1.44%)
Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More

Acadia's (ACAD) study results and other pipeline updates have been the biotech sector's few key highlights during the past week.

BMY : 63.54 (-1.61%)
ACAD : 21.18 (-1.44%)
BHVN : 110.08 (-5.10%)
VIR : 33.46 (+0.97%)
Intel, AutoZone rise; Clorox, HealthEquity fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Tuesday:

ACAD : 21.18 (-1.44%)
MIME : 79.91 (+0.54%)
CLX : 178.60 (+1.49%)
MDB : 375.57 (-3.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104...

See More

Key Turning Points

3rd Resistance Point 22.96
2nd Resistance Point 22.50
1st Resistance Point 21.84
Last Price 21.18
1st Support Level 20.73
2nd Support Level 20.27
3rd Support Level 19.61

See More

52-Week High 54.58
Fibonacci 61.8% 39.72
Fibonacci 50% 35.13
Fibonacci 38.2% 30.54
Last Price 21.18
52-Week Low 15.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar